Want to track SRTA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth
Strata Critical Medical is rated 'Buy' with a 12–24 month horizon, targeting 30–35% upside as valuation remains attractive despite a recent rally. SRTA's transformation into a pure-play medical logistics provider, robust FY25 results, and margin expansion underpin confidence in forward guidance. Industry tailwinds, regulatory catalysts, and an aggressive acquisition strategy position SRTA for sustained revenue and EBITDA growth, with FY26 guidance implying an 11.6% EBITDA margin.
Seekingalpha | 2 months ago
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Seekingalpha | 3 months ago
